Study of SGR-2921 in Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome

Conditions:   Acute Myeloid Leukemia;   High-Risk and Very High-Risk Myelodysplastic Syndromes Intervention:   Drug: SGR-2921 Sponsor:   Schrödinger, Inc. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials